Wall Street Zen Upgrades GoodRx (NASDAQ:GDRX) to “Buy”

Posted by on Aug 17th, 2026

GoodRx (NASDAQ:GDRX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

GDRX has been the subject of a number of other reports. Wells Fargo & Company lifted their price objective on shares of GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Leerink Partners set a $5.00 price target on GoodRx in a research report on Thursday, August 6th. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. UBS Group upped their price objective on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a report on Thursday. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $4.00 price objective on shares of GoodRx in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.14.

View Our Latest Stock Report on GDRX

GoodRx Price Performance

GDRX stock opened at $3.73 on Friday. The company’s 50 day moving average is $3.03 and its 200 day moving average is $2.59. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 93.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx has a 1-year low of $1.77 and a 1-year high of $5.81.

GoodRx (NASDAQ:GDRX – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period in the previous year, the business posted $0.09 earnings per share. GoodRx’s revenue for the quarter was down 1.3% on a year-over-year basis. Sell-side analysts predict that GoodRx will post 0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P purchased a new stake in GoodRx during the 4th quarter valued at about $1,585,000. LSV Asset Management increased its stake in GoodRx by 20.0% in the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after purchasing an additional 471,319 shares during the period. Prescott Group Capital Management L.L.C. bought a new stake in GoodRx in the fourth quarter valued at approximately $4,812,000. Northwestern Mutual Wealth Management Co. lifted its position in GoodRx by 10,242.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of GoodRx by 275.0% during the first quarter. Assenagon Asset Management S.A. now owns 517,576 shares of the company’s stock valued at $1,014,000 after purchasing an additional 379,546 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Featured Articles

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.